JP2844103B2 - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JP2844103B2 JP2844103B2 JP2981890A JP2981890A JP2844103B2 JP 2844103 B2 JP2844103 B2 JP 2844103B2 JP 2981890 A JP2981890 A JP 2981890A JP 2981890 A JP2981890 A JP 2981890A JP 2844103 B2 JP2844103 B2 JP 2844103B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- kojic acid
- external preparation
- present
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、皮膚外用剤に関し、更に詳細には、優れた
細胞賦活作用を有し、外傷、ひび、あかぎれなどの改善
並びに創傷治癒促進効果に有効な皮膚外用剤に関する。Description: FIELD OF THE INVENTION The present invention relates to an external preparation for skin, and more particularly, it has an excellent cell activating effect, improves wounds, cracks, irritations and the like, and promotes wound healing. The present invention relates to an external preparation for skin which is effective for skin.
従来、細胞賦活や創傷治療、すなわち切創の治療やひ
げそり後の傷の治療、ひび、あかぎれ、ただれ、痔疾、
火傷などの改善のためい用いられる皮膚外用剤の薬効成
分としては、一般にアラントイン及びその誘導体、牛血
液除蛋白質、シコンエキス、アロエエキス、人参エキ
ス、プラセンタエキスなどが知られている。Conventionally, cell activation and wound treatment, that is, treatment of cut wounds and wounds after shaving, cracks, irritations, sores, hemorrhoids,
As a medicinal component of an external preparation for skin used for improving burns and the like, generally, allantoin and its derivatives, bovine blood deproteinization protein, sicon extract, aloe extract, ginseng extract, placenta extract and the like are known.
しかしながら、これらの薬効成分を含む皮膚外用剤で
は充分な効果を得ることができず、このため、顕著な細
胞賦活作用を有する皮膚外用剤が望まれていた。However, a skin external preparation containing these medicinal ingredients cannot provide a sufficient effect, and therefore, a skin external preparation having a remarkable cell activating action has been desired.
一方、コウジ酸又はその誘導体は、メラニン生成抑制
作用を有していることが知られている（特開昭53−1873
9号公報、特開昭56−7776号公報、特開昭56−79616号公
報、特開昭59−33207号公報等）。しかし、これらコウ
ジ酸又はその誘導体に関する他の効果については未だ知
られていなかった。On the other hand, kojic acid or a derivative thereof is known to have a melanin production inhibitory action (JP-A-53-1873).
No. 9, JP-A-56-7776, JP-A-56-79616, JP-A-59-33207, etc.). However, other effects of these kojic acids or derivatives thereof have not been known yet.
かかる実情において、本発明者らは、コウジ酸の薬理
作用について鋭意研究を重ねた結果、コウジ酸及び／又
はその誘導体と、特定の化合物を組み合わせることによ
り、顕著な細胞賦活作用を有する皮膚外用剤が得られる
ことを見出し本発明を完成した。Under such circumstances, the present inventors have conducted intensive studies on the pharmacological action of kojic acid, and as a result, by combining kojic acid and / or its derivative with a specific compound, a skin external preparation having a remarkable cell-activating effect. Were obtained, and the present invention was completed.
すなわち、本発明は、（Ａ）及び（Ｂ） （Ａ）コウジ酸及び／又はその誘導体 （Ｂ）アデノシン三リン酸、アデノシン二リン酸、アデ
ノシン一リン酸、コハク酸及びこれらの誘導体から選ば
れる一種又は二種以上 を含有することを特徴とする皮膚外用剤を提供するもの
である。That is, the present invention is selected from (A) and (B) (A) kojic acid and / or a derivative thereof (B) adenosine triphosphate, adenosine diphosphate, adenosine monophosphate, succinic acid, and derivatives thereof. It is intended to provide a skin external preparation characterized by containing one or more kinds.
本発明において、有効成分として用いれらる（Ａ）成
分のコウジ酸又はその誘導体は、次の一般式（Ｉ） （式中、R1及びR2は、同一又は異なっても良く、水素原
子又は炭素数３〜22のアシル基又はアルキル基を示す） で表わされるものである。In the present invention, kojic acid or a derivative thereof of the component (A) used as an active ingredient is represented by the following general formula (I) (Wherein, R 1 and R 2 may be the same or different and represent a hydrogen atom or an acyl group or an alkyl group having 3 to 22 carbon atoms).
コウジ酸は、アスペルギルス属、ペニシリウム属、ア
セトバクター属等の微生物などによる発酵生成物から抽
出、精製したものでも、精製工程を省いた抽出物のまま
のものでもよく、さらに、合成によって得られるもので
もよい。Kojic acid may be extracted and purified from fermentation products of microorganisms such as Aspergillus, Penicillium, Acetobacter, etc., or may be the extract as it is without the purification step, and further obtained by synthesis. May be.
また、コウジ酸誘導体としては、上記コウジ酸から合
成されるものが使用でき、そのエステルとしては、例え
ばコウジ酸モノブチレート、コウジ酸モノカプレート、
コウジ酸モノパルミテート、コウジ酸モノステアレー
ト、コウジ酸モノシンナメート又はコウジ酸モノベンゾ
エートなどのモノエステル；コウジ酸ジブチレート、コ
ウジ酸ジパルミテート、コウジ酸ジステアレート又はコ
ウジ酸ジオレエートなどのジエステル等が挙げられる。As the kojic acid derivative, those synthesized from the above-mentioned kojic acid can be used, and as the ester thereof, for example, kojic acid monobutyrate, kojic acid monocaprate,
Monoesters such as kojic acid monopalmitate, kojic acid monostearate, kojic acid monocinnamate or kojic acid monobenzoate; diesters such as kojic acid dibutyrate, kojic acid dipalmitate, kojic acid distearate or kojic acid diolate, and the like. .
これらコウジ酸及びその誘導体は、一種又は二種以上
を組合わせて用いることができ、また、皮膚外用剤の細
胞賦活作用及び経時安定性の点から、全組成中に0.0001
〜５重量％（以下、単に％で示す）、特に0.01〜３％配
合するのが好ましい。These kojic acid and its derivatives can be used alone or in combination of two or more.In view of the cell activating action and the stability over time of the external preparation for skin, 0.0001 in the total composition.
-5% by weight (hereinafter simply indicated as%), particularly preferably 0.01-3%.
本発明の（Ｂ）成分であるアデノシン三リン酸、アデ
ノシン二リン酸、アデノシン一リン酸（以下、それぞれ
ATP、ADP、AMPという）、コハク酸は、生体内でエネル
ギー伝達系、生成系に関与する物質である。本発明にお
いては、これらATP、ADP、AMP、コハク酸の他、これら
の塩やエステル等の誘導体も使用することができ、例え
ば、ATP、ADP又はAMPの一ナトリウム塩、二ナトリウム
塩、三ナトリウム塩、一カリウム塩、二カリウム塩又は
三カリウム塩、コハク酸のカルシウム塩、二ナトリウム
塩、モノメチルエステル又はジエチルエステル等が挙げ
られる。これらは、一種又は二種以上を組み合わせて用
いることができ、また、皮膚外用剤の細胞賦活作用およ
び経時安定性の点から、全組成中に0.001〜５％、特に
0.01〜３％配合するのが好ましい。The components (B) of the present invention, adenosine triphosphate, adenosine diphosphate, and adenosine monophosphate (hereinafter, respectively,
ATP, ADP, and AMP) and succinic acid are substances involved in the energy transfer system and the production system in vivo. In the present invention, in addition to these ATP, ADP, AMP and succinic acid, derivatives such as salts and esters thereof can also be used, for example, monosodium salt, disodium salt, trisodium salt of ATP, ADP or AMP. Salt, monopotassium salt, dipotassium salt or tripotassium salt, calcium salt of succinic acid, disodium salt, monomethyl ester or diethyl ester and the like. These can be used alone or in combination of two or more, and from the viewpoint of cell activating action and stability over time of the external preparation for skin, 0.001 to 5%, particularly
It is preferable to mix 0.01 to 3%.
さらに、本発明の皮膚外用剤には、前記必須成分の
他、通常の皮膚外用剤に用いられる水性成分、粉体、界
面活性剤、油剤、保湿剤、アルコール類、pH調整剤、防
腐剤、色素、酸化防止剤、紫外線吸収剤、増粘剤、香
料、美肌用成分等を必要に応じて適宜配合することがで
きる。また、細胞賦活作用を有する他の公知の薬剤、例
えばアラントイン及びその誘導体、シコンエキス、アロ
エエキス等を配合してもよい。Further, the external preparation for skin of the present invention includes, in addition to the essential components, aqueous components, powders, surfactants, oils, humectants, alcohols, pH adjusters, preservatives, and the like used in ordinary external preparations for skin. A dye, an antioxidant, an ultraviolet absorber, a thickener, a fragrance, a component for beautiful skin, and the like can be appropriately compounded as necessary. Further, other known drugs having a cell activating effect, such as allantoin and its derivatives, sicon extract, aloe extract, and the like, may be added.
本発明の皮膚外用剤は、必須成分であるコウジ酸及び
／又はその誘導体と、ATP、ADP、AMP、コハク酸及びこ
れらの誘導体から選ばれる成分を配合し、常法に従って
製造することができる。そして、乳液、クリーム、化粧
水、パック、洗浄料等や、その他分散状、顆粒状、軟膏
状等の医薬用、医薬部外用又は化粧用の皮膚外用剤とし
て適用することができる。The skin external preparation of the present invention can be produced according to a conventional method by blending essential components of kojic acid and / or a derivative thereof and components selected from ATP, ADP, AMP, succinic acid and derivatives thereof. Then, it can be applied as an emulsion, cream, lotion, pack, cleaning agent, and the like, or as a pharmaceutical, quasi-drug or cosmetic external preparation such as dispersion, granule, ointment and the like.
次に試験例及び実施例を挙げて本発明を更に詳細に説
明するが、本発明はこれらに限定されるものではない。Next, the present invention will be described in more detail with reference to Test Examples and Examples, but the present invention is not limited thereto.
試験例１ 創傷治癒試験： 生後８週令のWistar系雄性ラットを、１群５匹として
実験に供した。ラットの背部を剃毛した後、麻酔下、正
中線に対称となるように左右２ヶ所を4cmにわたり皮膚
を切開し、一方を薬剤塗布部位、他方を対照部位とす
る。ただちに、両切開部を３ヶ所縫合し、消毒用エタノ
ールで清拭しておく。縫合部のうち、薬剤塗布部位には
第１表に示した試料〜（生理食塩水に溶解）の１種
を、対照部位には生理食塩水を0.1mlずつ、１日２回、
１週間塗布した。Test Example 1 Wound healing test: Male Wistar rats, 8 weeks old, were subjected to the experiment in groups of 5 rats. After shaving the back of the rat, under anesthesia, the skin is incised in two places on the left and right over 4 cm so as to be symmetrical to the midline, one of which is a drug application site and the other is a control site. Immediately, suture the three incisions at three places and clean with ethanol for disinfection. Of the sutures, one of the samples shown in Table 1 to (dissolved in physiological saline) was applied to the drug application site, and 0.1 ml of saline was applied twice daily to the control site.
It was applied for one week.
１週間後、背部皮膚を剥離して、切開創を中心に短冊
状の切片を作成した。皮膚切片の張力強度を、レオメー
ターNRM−2002J（不動工業（株）製）を用いて測定し
た。One week later, the back skin was peeled off, and a strip-shaped section centered on the incision was made. The tensile strength of the skin section was measured using a rheometer NRM-2002J (manufactured by Fudo Industry Co., Ltd.).
得られた測定値から、次式により創傷治癒率を算出し
た。結果を第１表に示す。From the obtained measured values, the wound healing rate was calculated by the following equation. The results are shown in Table 1.
第１表から明らかな如く、コウジ酸とATP、ADP、AMP
又はコハク酸とを組み合わせた場合には、それぞれを単
独で使用した場合と比較して、明らかに創傷治癒率が高
く、相乗的な創傷治癒促進効果が認められた。 As is clear from Table 1, kojic acid and ATP, ADP, AMP
Alternatively, when combined with succinic acid, the wound healing rate was clearly higher than when each was used alone, and a synergistic wound healing promoting effect was observed.
実施例１ クリーム： 第３表に示す組成のクリームを製造し、肌荒れ改善効
果について評価した。結果を第３表に示す。Example 1 Cream: Creams having the compositions shown in Table 3 were produced and evaluated for the effect of improving skin roughness. The results are shown in Table 3.
（製法） A.（11）〜（17）を加熱混合し、70℃に保つ。(Production method) A. (11) to (17) are heated and mixed, and kept at 70 ° C.
B.（１）〜（10）を加熱混合し、70℃に保つ。B. Heat-mix (1)-(10) and keep at 70 ° C.
C.BをＡに加えて混合し、均一に乳化する。Add C.B to A, mix and emulsify uniformly.
D.Cを冷却後、（18）を加え、均一に混合してクリーム
を得た。After cooling the DC, (18) was added and mixed uniformly to obtain a cream.
（評価方法） 健常な男性105名をパネルとし、１群15名として、顔
面半面に本発明品１〜３又は比較品１〜４のクリーム
を、他の半面に比較品５のクリームを、それぞれ１日１
回、２週間塗布した。(Evaluation method) 105 healthy men were used as panels, and 15 creams per group, with creams of the present invention products 1 to 3 or comparative products 1 to 4 on one face, and cream of comparative product 5 on the other half. 1 per day
Application for 2 weeks.
２週間後、顔面皮膚レプリカを採取し、第２表に示す
基準により評価した。得られた本発明品１〜３、比較品
１〜４のクリーム塗布部位のレプリカのスコアから比較
品５のクリーム塗布部位のレプリカのスコアを引いた値
を肌荒れ改善度とした。尚、パネルには、試験開始前の
スコアが１又は２の男性を選んだ。Two weeks later, facial skin replicas were collected and evaluated according to the criteria shown in Table 2. The value obtained by subtracting the score of the replica of the cream application site of the comparative product 5 from the obtained score of the replica of the cream application site of the present invention products 1 to 3 and comparative products 1 to 4 was defined as the degree of skin roughness improvement. In addition, the male whose score before the test was 1 or 2 was selected for the panel.
第３表から明らかな如く、本発明品１〜３のクリーム
は、優れた肌荒れ改善効果を示し、コウジ酸とATP等と
の相乗効果が認められた。 As is clear from Table 3, the creams of the products 1 to 3 of the present invention exhibited an excellent skin roughness improving effect, and a synergistic effect of kojic acid and ATP was recognized.
実施例２ 化粧水： ＜処方＞ （％） （１）ポリオキシエチレン硬化ヒマシ油（60E.0.） 1.0 （２）エチルアルコール 15.0 （３）防腐剤 0.1 （４）コハク酸ジメチルエステル 0.1 （５）香料 適量 （６）コウジ酸 1.0 （７）マンニット 1.0 （８）セイヨウトチノキエキス 0.5 （９）クエン酸 0.1 （10）クエン酸ナトリウム 0.3 （11）1,3−ブチレングリコール 4.0 （12）精製水 残量 ＜製法＞ A.（１）〜（５）を加熱、混合溶解する。Example 2 Lotion: <Formulation> (%) (1) Polyoxyethylene hydrogenated castor oil (60E.0.) 1.0 (2) Ethyl alcohol 15.0 (3) Preservative 0.1 (4) Dimethyl succinate 0.1 (5) ) Fragrance appropriate amount (6) Kojic acid 1.0 (7) Mannit 1.0 (8) Horse chestnut extract 0.5 (9) Citric acid 0.1 (10) Sodium citrate 0.3 (11) 1,3-butylene glycol 4.0 (12) Purified water Residual amount <Production method> A. Heat and mix (1) to (5).
B.（６）〜（12）を加熱、混合溶解する。B. Heat and mix (6) to (12).
C.AとＢを混合して、化粧水を得た。C. A and B were mixed to obtain a lotion.
実施例３ 乳液： ＜処方＞ （％） （１）ポリオキシエチレンソルビタンモノステアレート
（10E.0.） 1.0 （２）ポキオキシエチレンソルビットテトラオレエート
（60E.0.） 0.5 （３）グリセリルモノステアレート 1.0 （４）ステアリン酸 0.5 （５）ベヘニルアルコール 0.5 （６）スクワラン 8.0 （７）グレープシードオイル 5.0 （８）防腐剤 0.1 （９）コウジ酸ジステアレート 0.5 （10）ATP二ナトリウム塩 0.05 （11）カルボキシビニルポリマー 0.1 （12）水酸化ナトリウム 0.05 （13）エチルアルコール 5.0 （14）精製水 残量 （15）香料 適量 ＜製法＞ A.（10）〜（14）を加熱混合し、70℃に保つ。Example 3 Emulsion: <Formulation> (%) (1) Polyoxyethylene sorbitan monostearate (10E.0.) 1.0 (2) Poxyoxyethylene sorbite tetraoleate (60E.0.) 0.5 (3) Glyceryl mono Stearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Squalane 8.0 (7) Grape seed oil 5.0 (8) Preservative 0.1 (9) Kojic acid distearate 0.5 (10) ATP disodium salt 0.05 (11) Carboxyvinyl polymer 0.1 (12) Sodium hydroxide 0.05 (13) Ethyl alcohol 5.0 (14) Remaining purified water (15) Appropriate amount of perfume <Production method> A. Mix (10) to (14) by heating and keep at 70 ° C .
B.（１）〜（９）を加熱混合し、70℃に保つ。B. Heat-mix (1)-(9) and keep at 70 ° C.
C.BをＡに加えて混合し、均一に乳化する。Add C.B to A, mix and emulsify uniformly.
D.Cを冷却後、（18）を加え、均一に混合して乳液を得
た。After cooling the DC, (18) was added and mixed homogeneously to obtain an emulsion.
実施例４ 軟膏： ＜処方＞ （％） （１）ステアリン酸 18.0 （２）セタノール 4.0 （３）トリエタノールアミン 2.0 （４）グリセリン 5.0 （５）コウジ酸 1.0 （６）ADP 1.0 （７）感光素401号 0.002 （８）塩化リゾチーム 1.0 （９）精製水 残量 ＜製法＞ A.（３）、（４）及び（９）の一部を加熱混合し、75℃
に保つ。Example 4 Ointment: <Formulation> (%) (1) Stearic acid 18.0 (2) Cetanol 4.0 (3) Triethanolamine 2.0 (4) Glycerin 5.0 (5) Kojic acid 1.0 (6) ADP 1.0 (7) Photosensitizer No. 401 0.002 (8) Lysozyme chloride 1.0 (9) Remaining purified water <Production method> A. A part of (3), (4) and (9) is heated and mixed, and 75 ℃
To keep.
B.（１）及び（２）を加熱混合し、75℃に保つ。B. Heat mix (1) and (2) and keep at 75 ° C.
C.AをＢに徐々に加える。C. Add A slowly to B.
D.Cを冷却しながら（９）の残部で溶解した（５）〜
（８）を加え、軟膏を得た。Dissolved in the remainder of (9) while cooling DC (5)-
(8) was added to obtain an ointment.
以上詳述した如く、本発明の皮膚外用剤は、優れた細
胞賦活作用を有し、外傷、ひび、あかぎれ等による肌荒
れの改善、創傷治癒促進等に有効である。As described in detail above, the external preparation for skin of the present invention has an excellent cell activating effect, and is effective for improving skin roughness due to trauma, cracks, irritations and the like, promoting wound healing, and the like.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 31/70 ＡＧＡ Ａ６１Ｋ 31/70 ＡＧＡ (72)発明者 近藤 健 東京都北区栄町48番18号 株式会社小林 コーセー研究所内 (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 31/35 A61K 31/19 A61K 31/70 ＣＡ（ＳＴＮ)────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/70 AGA A61K 31/70 AGA (72) Inventor Ken Kondo 48-18 Sakaemachi, Kita-ku, Tokyo Kobayashi Kose Research Institute Co., Ltd. (58) Field surveyed (Int.Cl. 6 , DB name) A61K 31/35 A61K 31/19 A61K 31/70 CA (STN)
Claims (1)
はその誘導体 （Ｂ）アデノシン三リン酸、アデノシン二リン酸、アデ
ノシン一リン酸、コハク酸及びこれらの誘導体から選ば
れる一種又は二種以上 を含有することを特徴とする皮膚外用剤。(A) and (B) (A) Kojic acid and / or a derivative thereof (B) One selected from adenosine triphosphate, adenosine diphosphate, adenosine monophosphate, succinic acid and derivatives thereof Or an external preparation for skin, characterized by containing two or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2981890A JP2844103B2 (en) | 1990-02-09 | 1990-02-09 | External preparation for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2981890A JP2844103B2 (en) | 1990-02-09 | 1990-02-09 | External preparation for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03236320A JPH03236320A (en) | 1991-10-22 |
| JP2844103B2 true JP2844103B2 (en) | 1999-01-06 |
Family
ID=12286604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2981890A Expired - Lifetime JP2844103B2 (en) | 1990-02-09 | 1990-02-09 | External preparation for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2844103B2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2695034B1 (en) | 1992-09-01 | 1994-10-07 | Oreal | Cosmetic or pharmaceutical composition comprising in combination a peroxidase and a singlet anti-oxygen agent. |
| AU7811094A (en) * | 1993-11-27 | 1995-06-13 | Knoll Aktiengesellschaft | Compositions comprising iminium ion scavengers and/or nitrite scavengers |
| CH688760A5 (en) * | 1995-04-28 | 1998-03-13 | Synergen Ag | A topical preparation for promotion of muscle growth. |
| GB9701374D0 (en) * | 1997-01-23 | 1997-03-12 | Univ Liverpool | Purinergic agonists and antagonists |
| KR100426753B1 (en) * | 1998-04-27 | 2004-04-13 | 칼라 액세스, 인크. | Composition and Method for Treatment of Aging Skin |
| CA2362116A1 (en) * | 1999-04-05 | 2000-10-12 | Igor Anatolievich Pomytkin | Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
| JP2002293728A (en) * | 2001-03-30 | 2002-10-09 | Sansho Seiyaku Co Ltd | Astringent cosmetic |
| JP2002293729A (en) * | 2001-03-30 | 2002-10-09 | Sansho Seiyaku Co Ltd | Tissue-repairing agent |
| JP4518367B2 (en) * | 2002-03-25 | 2010-08-04 | 株式会社資生堂 | Pore reducing agent |
| US7056529B2 (en) * | 2002-05-14 | 2006-06-06 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
| CN102458351B (en) * | 2009-06-19 | 2014-04-16 | 大塚制药株式会社 | Agent for preventing or treating abnormality in skin water permeation function |
| CN109820803B (en) * | 2018-12-29 | 2021-11-12 | 东晟源研究院(广州)有限公司 | Composition capable of removing skin toxin and increasing skin resistance and application thereof |
-
1990
- 1990-02-09 JP JP2981890A patent/JP2844103B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03236320A (en) | 1991-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4564471B2 (en) | Composition suitable for external use | |
| JPH09143063A (en) | Composition suitable for external use | |
| JPH08208488A (en) | Skin preparation for external use | |
| WO1999059580A1 (en) | Preventives/remedies for skin diseases | |
| JP2001517688A (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
| JP2844103B2 (en) | External preparation for skin | |
| JPH07277939A (en) | Skin external preparation | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| JP3202810B2 (en) | Cosmetics | |
| JPH09157153A (en) | Preparation for external use for skin | |
| JP3251635B2 (en) | External preparation for skin | |
| JPH09183718A (en) | Composition suitable for external application | |
| JP3881411B2 (en) | Composition suitable for external use | |
| JPH06336422A (en) | External agent for skin | |
| JP3507635B2 (en) | Composition suitable for external use | |
| JPH0899860A (en) | Skin external agent | |
| JP2780803B2 (en) | External preparation for skin | |
| JPH06279294A (en) | Collagen synthesis promoter | |
| JPH1192326A (en) | Skin preparation for external use | |
| JP2781982B2 (en) | External preparation for skin | |
| JPH04360820A (en) | Cosmetic | |
| JP2565516B2 (en) | Topical skin | |
| JP3443130B2 (en) | External preparation for skin | |
| JPH10279421A (en) | Preparation for external use for skin | |
| JP2001288045A (en) | Composition for scalp and hair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20071030 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081030 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081030 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091030 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101030 Year of fee payment: 12 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101030 Year of fee payment: 12 |